| Sonstiges: |
- Nachgewiesen in: USPTO Patent Applications
- Sprachen: English
- Document Number: 20240124594
- Publication Date: April 18, 2024
- Appl. No: 18/263929
- Application Filed: February 02, 2022
- Claim: 1. A method of treating a subject that has cardiovascular disease (CVD), or Systemic Sclerosis (SS), comprising: treating a subject that has CVD or SS with at least one of the following: a) IgG3 β1-Adrenergic Receptor antibodies (IgG3 β1AR antibodies) or antigen-binding portion thereof, b) an antigenic protein that elicits the production of said IgG3 β1AR antibodies in said subject; or c) a vector comprising a nucleic acid sequence encoding: i) said IgG3 β1AR antibodies, ii) antigen-binding portion thereof, or iii) said antigenic protein.
- Claim: 2. The method of claim 1, wherein said subject is negative, or lower than a control, for IgG3 β1AR antibodies prior to said treatment.
- Claim: 3. The method of claim 1, wherein said CVD comprises dilated cardiomyopathy.
- Claim: 4. The method of claim 1, wherein said IgG3 β1AR antibodies are monoclonal.
- Claim: 5. The method of claim 1, further comprising: testing a blood, serum, or plasma sample from said subject for the presence of IgG3 β1AR antibodies prior to said treatment.
- Claim: 6. The method of claim 1, further comprising: testing a blood, serum, or plasma sample from said subject for the presence of IgG3 β1AR antibodies after said treatment.
- Claim: 7. The method of claim 1, wherein said antigenic protein comprises at least a portion of SEQ ID NO:1.
- Claim: 8. The method of claim 1, wherein said antigenic protein comprises SEQ ID NO:2.
- Claim: 9. The method of claim 1, wherein said antigenic protein comprises at least 15 consecutive amino acids from SEQ ID NO:2.
- Claim: 10. The method of claim 1, wherein said antigenic protein comprises a peptide with at least 90% amino acid sequence identity with SEQ ID NO:2.
- Claim: 11. The method of claim 1, wherein said nucleic acid sequence comprises at least 50 consecutive nucleotides from SEQ ID NO:3.
- Claim: 12. The method of claim 1, wherein said subject is a human.
- Claim: 13. The method of claim 1, wherein said IgG3 β1AR antibodies, or antigen-binding portion thereof, are human or humanized antibodies, and said subject is a human.
- Claim: 14. The method of claim 1, wherein said treating comprises intravenous treatment.
- Claim: 15. The method of claim 1, wherein said vectors comprises a plasmid, adeno-associated virus, or adeno-associated virus.
- Claim: 16. The method of claim 1, wherein said subject is on a β-blocker prior to said treatment.
- Claim: 17. The method of claim 1, further comprising: administering a β-blocker to said subject prior to, during, or after said treatment.
- Claim: 18. The method of claim 17, wherein said β-blocker is selected from the group consisting of: Acebutolol, Atenolol, Bisoprolol, Metoprolol, Nadolol, Nebivolol, and Propranolol.
- Claim: 19. The method of claim 1, wherein said IgG3 β1AR antibodies are autoantibodies purified from a blood, serum, or plasma sample of a donor or the subject themselves.
- Claim: 20. A kits, system, or composition comprising: a) at least one of the following: i) IgG3 β1-Adrenergic Receptor antibodies (IgG3 β1AR antibodies) or antigen-binding portion thereof; ii) an antigenic protein that elicits the production of IgG3 β1AR antibodies in a subject; or iii) a vector comprising a nucleic acid sequence encoding: i) said IgG3 β1AR antibodies, ii) said antigen-binding portion thereof, or iii) said antigenic protein, and b) a β-blocker.
- Claim: 21. A method comprising: a) receiving results of, or conducting, an IgG3 β1-Adrenergic Receptor IgG3 β1AR antibodies (IgG3 β1AR antibodies) level analysis on a sample from a subject with cardiovascular disease (CVD) or Systemic Sclerosis (SS), and b) performing at least one of the following after identifying said sample as having higher levels of said IgG3 β1AR antibodies compared to control levels, i) treating said subject with a beta-blocker; ii) treating said subject with IgG3 β1AR antibodies or antigen-binding portion thereof; iii) treating said subject with an antigenic protein that elicits the production of said IgG3 β1AR antibodies in said subject; iv) a vector comprising a nucleic acid sequence encoding: i) said IgG3 β1AR antibodies, ii) said antigen-binding portion thereof, or iii) said antigenic protein; and/or v) providing a report to said patient or medical personnel treating said patient, indicating said subject is suitable for, or should be, treated with: A) said beta-blocker, B) said IgG3 β1AR antibodies or antigen-binding portion thereof, C) said antigenic protein, and/or D) said vector.
- Claim: 22. The method of claim 21, wherein said control levels are from the general population or CVD patients not stratified by IgG3 β1AR antibody levels.
- Current International Class: 07; 61; 61; 07; 12
|
